<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>STTR Phase I:  Development of an Intranasal Vaccine for COVID-19</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>10/01/2020</AwardEffectiveDate>
<AwardExpirationDate>03/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>256000.00</AwardTotalIntnAmount>
<AwardAmount>276000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Kaitlin Bratlie</SignBlockName>
<PO_EMAI>kbratlie@nsf.gov</PO_EMAI>
<PO_PHON>7032922638</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project is development of a novel, safe and effective, non-invasive, vaccine for the COVID-19 pandemic.  Currently there is no approved vaccine for SARS-CoV-2, and some candidates are administered intramuscularly. The proposed intranasal vaccine directly interacts with the respiratory tract and may provide improved protection and virus clearance. The proposed vaccine is non-invasive, easy to administer, and may be effective in a single dose, thus impacting future social distancing needs. &lt;br/&gt;&lt;br/&gt;This Small Business Technology Transfer (STTR) Phase I project will develop an intranasal coronavirus vaccine and determine the most promising formulation, with tasks including: 1) synthesis of novel coronavirus antigens and formulation of intranasal vaccine using liposome nanoparticles, including antigen discovery, liposome nanoparticle formulation, and in vitro characterization; 2) preclinical testing of intranasal coronavirus vaccine in an animal model, including intranasal vaccination, serum antibody analysis, virus challenge and analysis of protection efficacy. The outcome of this Phase I study is to obtain an optimized nanoparticle intranasal vaccine formulation for induction of robust T and B cell responses specific to SARS-CoV-2 S and N protein.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>09/22/2020</MinAmdLetterDate>
<MaxAmdLetterDate>07/16/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2032325</AwardID>
<Investigator>
<FirstName>Maoqi</FirstName>
<LastName>Feng</LastName>
<PI_MID_INIT>M</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Maoqi M Feng</PI_FULL_NAME>
<EmailAddress>contact@polykalatech.com</EmailAddress>
<PI_PHON>2102484440</PI_PHON>
<NSF_ID>000783165</NSF_ID>
<StartDate>01/05/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Xingguo</FirstName>
<LastName>Cheng</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Xingguo Cheng</PI_FULL_NAME>
<EmailAddress>Xchengswri@gmail.com</EmailAddress>
<PI_PHON>2162696757</PI_PHON>
<NSF_ID>000794063</NSF_ID>
<StartDate>09/22/2020</StartDate>
<EndDate>01/05/2021</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Renukaradhya</FirstName>
<LastName>Gourapura</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Renukaradhya Gourapura</PI_FULL_NAME>
<EmailAddress>gourapura.1@osu.edu</EmailAddress>
<PI_PHON>3302633748</PI_PHON>
<NSF_ID>000826339</NSF_ID>
<StartDate>09/22/2020</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>DYNAMIC ENTROPY TECHNOLOGY, LLC</Name>
<CityName>San Antonio</CityName>
<ZipCode>782405404</ZipCode>
<PhoneNumber>2102484440</PhoneNumber>
<StreetAddress>4923 KENTON LK</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Texas</StateName>
<StateCode>TX</StateCode>
<CONGRESSDISTRICT>20</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>TX20</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>081331216</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>DYNAMIC ENTROPY TECHNOLOGY, LLC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[DYNAMIC ENTROPY TECHNOLOGY, LLC]]></Name>
<CityName>Devine</CityName>
<StateCode>TX</StateCode>
<ZipCode>780165145</ZipCode>
<StreetAddress><![CDATA[196 County Rd 7611]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Texas</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>23</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>TX23</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramElement>
<Code>8091</Code>
<Text>SBIR Outreach &amp; Tech. Assist</Text>
</ProgramElement>
<ProgramReference>
<Code>008E</Code>
<Text>Gene and Drug Delivery</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>6883</Code>
<Text>CHEMISTRY OF LIFE PROCESSES</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<ProgramReference>
<Code>8042</Code>
<Text>Health and Safety</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~256000</FUND_OBLG>
<FUND_OBLG>2021~20000</FUND_OBLG>
</Award>
</rootTag>
